Drug Trial Radar · NCT03367572
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,363
Actual
Start
Apr 19, 2018
Primary completion
Apr 13, 2024
Study completion Apr 13, 2024
Sponsor
- Lead sponsor
- University of Rochester NCORP Research BaseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Dec 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
Conditions
- Breast Carcinoma
Interventions
DexamethasoneDrug
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
Netupitant/Palonosetron HydrochlorideDrug
Given PO
OlanzapineDrug
Given PO
PlaceboOther
Given PO
ProchlorperazineDrug
Given PO
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or Olanzapine to Control Arm)Time frame: Nausea measured at Cycle 1 Chemotherapy (15 time points which is Days 1,2,3,4) and also measured at Cycle 2 Chemotherapy (16 time points which is Days 1,2,3,4)
- Average Nausea Defined as the [AVERAGE] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or Olanzapine to Control Arm)Time frame: Nausea measured at Cycle 1 Chemotherapy (15 time points which is Days 1,2,3,4) and also measured at Cycle 2 Chemotherapy (16 time points which is Days 1,2,3,4)
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Hawaii MU NCORP
Honolulu, Hawaii
Decatur Memorial Hospital
Decatur, Illinois
Gulf South MU-NCORP
New Orleans, Louisiana
Michigan Cancer Research Consortium
Ann Arbor, Michigan
Cancer Research Consortium of West Michigan
Grand Rapids, Michigan
Health Partners Inc
Minneapolis, Minnesota
Cancer Research for the Ozarks NCORP
Springfield, Missouri
Nevada Cancer Research Foundation NCORP
Las Vegas, Nevada
University of Rochester NCORP Research Base
Rochester, New York
Southeast Clinical Oncology Research Program
Winston-Salem, North Carolina
Columbus NCORP
Columbus, Ohio
Dayton Clinical Oncology Program
Dayton, Ohio
Geisinger Cancer Institute NCORP
Danville, Pennsylvania
Greenville NCORP
Greenville, South Carolina
Upstate Carolina NCORP
Spartanburg, South Carolina
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin
Gundersen Health System
La Crosse, Wisconsin
Aurora NCORP
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.